Skip to main content

Amgen, McKesson Partner to Improve Precision Medicine Access in Community Settings

NEW YORK – Drug and medical supplies distributor McKesson and pharmaceutical company Amgen on Friday said they have signed an agreement aimed at improving the care cancer patients receive at community practices, and in particular, increasing their access to precision and immuno-oncology treatments.

The partnership will be led by Ontada, McKesson's oncology technology and insights business, which conducts real-world data analysis that drugmakers like Amgen can use to improve drug development and commercialization efforts, and community oncology practices can use to address areas of unmet need.

Amgen and McKesson have already conducted a real-world study of molecular testing patterns among advanced non-small cell lung cancer patients receiving care from community oncologists. The results from this study are slated for publication next year.

In the latest partnership, Ontada and Amgen hope to expand on this work and increase awareness of molecular testing among cancer patients so they may have greater access to targeted treatments; pinpoint areas of unmet need; use real-world data to optimize use of biosimilars; advance new strategies for deploying immune-oncology treatments; and identify the right sequence of treatments to improve patient outcomes.

"Community oncology practices in the US are the backbone of oncology care for the vast majority of patients," Amgen Chief Medical Officer Darryl Sleep said in a statement. "Together with McKesson, our ultimate goal is to help community oncologists and their teams have rapid access to the latest innovations and insights to provide the best care possible where patients need it most."